4//SEC Filing
Tarriff Scott 4
Accession 0001209191-23-054333
CIK 0000827871other
Filed
Nov 2, 8:00 PM ET
Accepted
Nov 3, 4:39 PM ET
Size
8.3 KB
Accession
0001209191-23-054333
Insider Transaction Report
Form 4
Tarriff Scott
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2023-11-02$13.87/sh−10,694$148,326→ 545,447 total - Sale
Common Stock
2023-11-01$13.82/sh−10,925$150,984→ 556,141 total
Holdings
- 992,623(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.64 to $14.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.20 inclusive.
- [F4]The shares are held by the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the "Trust") for the benefit of the Reporting Person's spouse and children. The Reporting Person does not have investment control over the shares held by the Trust and disclaims beneficial ownership of the shares, except to any pecuniary interest therein, if any.
Documents
Issuer
EAGLE PHARMACEUTICALS, INC.
CIK 0000827871
Entity typeother
Related Parties
1- filerCIK 0001469124
Filing Metadata
- Form type
- 4
- Filed
- Nov 2, 8:00 PM ET
- Accepted
- Nov 3, 4:39 PM ET
- Size
- 8.3 KB